Articles tagged with Antivirals
Rapid resistance to novel antiviral therapy develops in response to direct antiviral drugs for hepatitis C virus (HCV) treatment. New HCV treatments face resistance concerns, experts advise careful prescription and monitoring to minimize rapid development. NS3-protease and NS5A inhibitors block essential enzymes for HCV replication.
A study finds that widespread discharge of inefficiently treated wastewater into rivers could occur if existing plans for antiviral and antibiotic use are implemented during a pandemic. This could lead to water quality deterioration at drinking water abstraction points, potentially causing eutrophication and environmental toxicity.
Scientists design artificial protocells with bait proteins that mimic henipavirus receptors, successfully entraping and deactivating experimental analogs of Nipah and Hendra viruses. This innovative technique could lead to the development of new antiviral drugs by exploiting the virus's basic infection mechanism.
A recent study found that hepatitis C patients in the US are twice as likely to be uninsured, with only a third having access to antiviral therapy. The lack of adequate health insurance coverage is a significant barrier to treatment, particularly for those with comorbidities.
Researchers at the University of Southampton successfully crystallized a key norovirus enzyme, paving the way for the development of an antiviral treatment. The breakthrough could help alleviate the significant public health burden caused by noroviruses, which are responsible for one million cases in the UK each year.
Two studies found that ITPA variants protect against treatment-related anemia in HCV patients, enabling safer use of antiviral therapy and reducing the need for erythropoietin treatment. The variants also help select patients who may tolerate higher doses of ribavirin, increasing the likelihood of viral clearance.
Researchers at the University of Minnesota have discovered how HIV binds to and destroys APOBEC3F, a specific human antiviral protein. By converting this protein to a more effective antiviral agent, they found that shielding of a common feature shared by related proteins may yield similar outcomes.
Researchers have made significant breakthroughs in understanding how HIV mutates and evades treatment, providing new insights into developing better tests and treatments for patients. The study found that a specific mutation allows the virus to resist two main families of drugs, highlighting the need for tailored therapies.
Recent studies reveal a rise in dual-resistance among certain influenza viruses, their increased transmission, and the limited availability of alternative treatment options. This poses significant public health concerns.
The Models of Infectious Disease Agent Study (MIDAS) researchers used computational modeling to predict the potential outcomes of different interventions for the H1N1 flu strain. The study found that vaccinating school-aged children substantially reduced overall disease spread and prevented up to 100 million additional cases.
Researchers found that patients taking oral antiviral medications had fewer recurrences of corneal disease and other eye-related manifestations. The study suggests that antiviral prophylaxis should be considered for patients with frequent recurrences, highlighting its potential to prevent vision loss.
A study of over 837,000 births in Denmark found no association between exposure to certain antiviral drugs and major birth defects. The findings suggest that acyclovir is safe for use in early pregnancy, while further research is needed on the safety of valacyclovir and famciclovir.
Researchers at the University of Edinburgh have developed a method to alter viral conditions, reducing mutation and building resistance. This approach can target multiple viruses simultaneously and is being explored for use in treating influenza.
A large multicentre study found that early antiviral treatment reduced hospitalization and intensive care admissions among transplant recipients with H1N1. Vaccination and preventive measures may also provide protection for this high-risk population.
Researchers at Thomas Jefferson University found that antiviral therapy prevents HCC recurrence and extends survival in CHB patients. The median survival was 60 months for those receiving antiviral therapy, compared to 12.5 months for those not receiving it.
Researchers at UCLA Medical Center found antiviral therapy during compensated cirrhosis to be the most cost-effective approach for treating HCV patients with advanced liver disease. Treatment initiated before progression to more advanced liver disease resulted in improved survival and decreased costs compared to other strategies.
Researchers found that sustained virologic response (SVR) prevents esophageal varices in patients with compensated hepatitis C (HCV)-induced cirrhosis. This study suggests that endoscopic surveillance can be safely delayed or avoided in these patients, reducing unnecessary invasive procedures.
Scientists have developed an immune-deficient mouse model to study CCHF virus behavior in humans, a significant step towards vaccine and antiviral development. The model can help evaluate the safety and effectiveness of potential treatments, addressing the lack of suitable animal models for testing.
Peroxisomes, organelles inside cells, can detect virus invasion signals and launch a limited antiviral offensive. Mitochondria follow up with a more definitive counterattack, indicating a potential new approach to rare conditions like peroxisome biogenesis disorders.
Researchers predict that a combination of drugs targeting three or more mutated strains of the hepatitis C virus is necessary to eradicate the virus. The findings suggest that a new treatment approach involving multiple direct-acting antivirals may be needed, potentially shortening treatment duration and improving cure rates.
A study found pregnant women had a disproportionately higher risk of death due to 2009 influenza A(H1N1) in the US. Early antiviral treatment was associated with fewer ICU admissions and deaths. Pregnant women are at increased risk due to changes in their immune, cardiac, and respiratory systems.
Two people with compromised immune systems developed drug-resistant strains of the 2009 H1N1 virus after less than two weeks on therapy. Both patients showed clinical resistance to oseltamivir and peramivir, emphasizing the need for alternative treatment strategies.
Researchers found that CS-8958 resulted in higher survival rates and lower virus levels than oseltamivir in mouse models. The novel compound also protected mice from lethal H5N1 infection when given before or after exposure to the virus.
Researchers found a single dose of CS-8958 administered two hours after infection resulted in higher survival rates and lower virus levels compared to standard oseltamivir treatment. The compound also protected mice against lethal H5N1 infection when given seven days before infection.
Researchers at Iowa State University's Ames Lab have discovered the binding site of antiviral drug amantadine on the flu virus. The study shows that amantadine blocks the flu virus by attaching to a site within a proton channel, preventing it from infecting healthy cells.
Researchers have developed a broad-spectrum antiviral compound that can stop a wide range of highly dangerous viruses, including those causing HIV, Ebola, and hepatitis C. The compound works by altering the lipid envelope of enveloped viruses, making them unable to fuse with host cells.
A targeted antiviral medication program, combined with aggressive hand sanitization and surface decontamination, was associated with containing the spread of H1N1 in a summer camp setting. The study found that the program reduced the attack rate of the virus from 1.8% to zero among campers.
Researchers have identified a broad-spectrum antiviral compound effective against HIV-1, influenza A, filoviruses, poxviruses, and other deadly diseases. The compound, LJ001, targets enveloped viruses by exploiting their biogenic reparative ability, resulting in permanent and irreversible damage.
Researchers found a family of naturally occurring antiviral agents in human cells that protected against most virus particles, including influenza A strains and West Nile virus. The proteins, called IFITM, worked by preventing the virus from attaching to cells, offering potential new ways to prevent and treat viral infections.
A new drug, SPC3649, developed by Santaris Pharma, targets liver cells and showed a substantial drop in blood levels of the virus in animals, continuing to work after treatment stopped. The study also suggests that this technology could be useful for treating other diseases like HIV, cancer, and inflammatory diseases.
Research suggests that only half of Americans with hepatitis C virus infection are aware of their diagnosis, leading to a decline in antiviral therapy treatment rates. By 2030, less than 15% of liver-related deaths from HCV will be prevented by antiviral therapy if the trend continues.
Antiviral medications prescribed for Bell's palsy are no more effective than placebo, while corticosteroids offer significant benefits. The review suggests further research should focus on discovering alternative causes and treatments for the condition.
A fraction of potential vaccine supply will be ready for distribution by October, but generous pledges from nine countries and two manufacturers will help protect vulnerable populations. The H1N1 virus is expected to infect one-third of the world's population, highlighting the need for effective vaccination strategies.
A study published in Gastroenterology found that men with chronic hepatitis C undergoing antiviral therapy experience common sexual dysfunction, including impairment of desire, function, and satisfaction. The average onset of sexual dysfunction was within four weeks of starting therapy.
A systematic review of 18 studies found corticosteroids alone reduce unsatisfactory recovery by 9%, while combined therapy with antiviral agents may offer a 5% absolute risk reduction. Corticosteroids are also associated with reduced synkinesis and autonomic dysfunction.
Researchers from Heidelberg University Hospital have identified a new target for treating chronic hepatitis C: the protein cyclophilin A. Inhibiting this protein blocks virus replication and has two complementary effects, making it a promising approach to therapy.
A recent study published in The Lancet Infectious Diseases suggests that extending the vaccination policy could be a more clinically effective and cost-effective strategy for treating seasonal flu. The study analyzed the effectiveness of antiviral treatments and found that vaccination may be a better option for healthy adults, while th...
Researchers warn that antiviral treatment for the elderly may not reduce mortality and could lead to increased resistance. Age-prioritized use of antivirals is suggested as a more efficient way to treat patients.
A landmark study finds that treatment with either of two standard antiviral drug therapies is safe and offers the best way for people infected with hepatitis C to prevent liver scarring, organ failure and death. The study showed that treating patients in early or less advanced stages of the disease leads to higher success rates.
Researchers discover potential drugs that block the first step in the infection process, preventing flu viruses from infecting cells. This breakthrough could lead to a new genre of antivirals and be used to develop treatments for other medical problems.
Researchers have developed a new ultra-sensitive detector that can detect respiratory syncytial virus (RSV) at lower levels than current standard assays. The device uses DNA hairpins attached to gold filaments, taking only minutes to produce results and suitable for use in pediatrician's offices.
A meta-analysis of published studies on Bell's palsy found no improved recovery with corticosteroids and antiviral combination therapy. Facial motor function recovery was not significantly different between the two groups.
A review by Dr David Fedson suggests that generic drugs like statins and fibrates could help manage the pandemic by regulating cell signalling pathways. However, the majority of the world's population will not have timely access to affordable supplies of vaccines and antiviral agents.
Researchers suggest using a small stockpile of a secondary antiviral drug to delay the development of resistance to primary drugs in flu pandemics. By treating only 1-1.5% of the population with a secondary drug, resistance to primary drugs can be substantially reduced.
A study published in the journal Pain found oxycodone to be an effective treatment for acute shingles pain, with patients experiencing a significant reduction in pain levels. The medication was more than twice as effective as a placebo in reducing pain, making it a promising option for treating this debilitating condition.
Patients who undergo liver transplantation for hepatitis B-related liver damage are at risk of disease recurrence if antiviral treatment is withdrawn, according to a new study. Researchers found that these patients lack cellular immunity against the disease, making lifelong antiviral therapy necessary.
Researchers document increasing resistance to adamantane-based antiviral drugs in over 30% of H5N1 samples. The study provides a framework for monitoring global evolution of drug resistance using molecular evolution tests and geographic visualization techniques.
Researchers analyzed 700 genome sequences of avian influenza strains to document resistance to adamantane antivirals. The study suggests that widespread antiviral drug use can accelerate the evolution of drug-resistant viruses, which can spread rapidly.
Researchers identified a small molecule called sfRNA that controls host response to viral infection. Targeting this molecule could lead to effective antiviral therapy for flavivirus diseases.
UT Southwestern researchers have developed a new strategy for broad-spectrum anti-viral drugs that targets a lipid molecule on infected cells, triggering the immune system to attack and destroy infected cells. The treatment, bavituximab, shows promise in treating viral diseases, including Lassa fever and cytomegalovirus.
Scientists discovered a key step in HIV's attack on brain cells and were able to reverse its effects by blocking the receptor. The discovery opens up a new avenue for researchers to explore in preventing or treating HIV's neurological effects, which have no currently approved treatment.
The NIAID has awarded a contract to the University of Washington to analyze and model virus-host interactions for SARS and bird flu. The research program will use systems biology approaches to generate predictive models that can be experimentally validated, providing valuable resources for the scientific community.
Researchers have developed a novel method to rapidly select anti-HBV agents for chronic hepatitis B patients with drug resistance. The approach involves replicating clinical HBV isolates in an in vitro model system, allowing for the identification of antiviral agents such as adefovir that can inhibit HBV replication.
Researchers have shown that early treatment for Hepatitis C virus (HCV) within the first months following an infection develops a rapid poly-functional immune response against HCV. This finding suggests that early treatment can restore immune response and help eliminate the virus rapidly, contributing to the development of new treatments.
A study of 883 treatment-naïve HIV patients found that atazanavir/ritonavir once daily was as effective as lopinavir/ritonavir twice daily in reducing viral load and increasing CD4 cells. The once-daily regimen had less gastrointestinal toxicity but a higher rate of hyperbilirubinemia, supporting its use as a first-line treatment option.
Researchers discovered that imiquimod, an immune response modifier, relies on the Opioid Growth Factor (OGF)-OGF receptor axis for its action. This finding provides new insights into the mechanism of imiquimod's antiviral and antitumor activity.
Researchers modelled pandemic flu to guide national planning, finding that prompt implementation of social-distancing measures combined with antiviral treatment and prophylaxis can reduce influenza cases by 83-94%.
New study reveals that timing of IL-7 treatment is crucial for enhancing antiviral immunity in mice. Administering IL-7 during the immune response contraction phase improves viral control and boosts vaccine-induced CD8+ T cell memory.
A study of patients with chronic hepatitis C found that silymarin, a popular herbal supplement, had no effect on HCV virus activity or liver inflammation. However, users reported fewer symptoms and improved quality of life compared to non-users.
New research reveals that timing of IL-7 treatment is crucial for enhancing antiviral immunity. Additionally, studies on cardiac development and wound healing have identified novel genes and mechanisms, offering potential therapeutic targets for chronic viral infections and cutaneous wounds.